quarterly numbers - dismal
burn rate - excessively rapid given limited cash longevity position, continuous fundraisers coming
D I L U T I O N = bag dudes get hosed over and over
next Reverse Split - when it falls to the $1s again
long-term shareholder value? ask historical long-term shareholders
thumbs down doesn't change historical facts
called 01.31.2013 phase III failure and stock price collapse
calling $1.90s before $4.00
They need about 7 more patients in the RCW study and they will go to FDA with data. Their investigators are impressed with results.
Almost 100% of patients have shown an objective response in RCWall. a gasp from some of their investigators.
Tumor control will be acceptable for FDA in chest wall breast cancer.
Endpoint deserves registrational consideration. humanitarian use program, RCWall. desperately needed therapy.
In some ways, RCW is similar to the Ebola treatment, i.e. the urgency to have a viable option to attempt to help patients.
FDA needs to show flexibility when dealing with this type of debilitating disease that has no treatment options. Should be approved
RCWall patients have no options and their quality of life can be beyond miserable. TDox has given many of these women relief.
buy at open sell around 09:55 for the run up ole Church thanks ole boy!
Sentiment: Strong Sell
You must be joking Check out their salaries on the profile page. "small buys' mean nothing
you may want to study upcoming financials, press releases, and listen to conference call before reaching any conclusions
re insiders buying
compared to their comp packages and freebie shares, small buys using their own money
I understand that really sucks bad but to new investors at this price, risk reward ratio heavily favors reward, especially with the new protocols in place.
Celsion * EGEN is a Silver Partner of the symposium;
Celsion is fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer.
The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlasTM, TheraSilenceTM and RASTTM.
Google tardox study. You'll get different sites, including clinicals.gov & oxford study. Good reading.
Targeted chemotherapy using focused ultrasound for liver metastases. Phase I trial listed on ct website between Celsion and Univ. Oxford. Looking to treat patients with liver metastases from lung, breast, or colorectal primary tumors.
Was there a pr on this?